Medical/Pharmaceuticals
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial
- Improvement of symptoms such as cough and dyspnea in mild patients over age 50 was reported to be as twice as fast and statistically significant in the treatment group (4 days) compared to the placebo control group (9 days). - Development is underway for potential combination therapies and nove...
2021-07-29 18:00
1701
Exyte Empowers the Biopharmaceutical Industry: First ExyCell(R) Facility Launched in Shanghai
STUTTGART, Germany and BERGISCH GLADBACH, Germany, July 29, 2021 /PRNewswire/ -- Exyte has successfully completed the construction of the first ExyCell® facility inChina, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products...
2021-07-29 16:25
3360
Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
SUZHOU, China, July 29, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administrat...
2021-07-29 07:46
2552
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325
SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, In...
2021-07-29 07:40
4466
Hemanext Partners with Sickle Cell 101 to Sponsor Sickle Cell Education
LEXINGTON, Mass. and SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of red blood cell (RBC) transfusions, has partnered withSickle Cell 101 (SC101), a Silicon Valley-ba...
2021-07-28 23:43
1644
Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial
SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant pr...
2021-07-28 21:08
1945
Leaf Space Applies Satellite Solutions to Enhance Connectivity for Home Monitoring of COVID-19 Patients with CARES Monitoring System
GSaaS solutions company is supported by the European Space Agency to test satellite enabled telemedicine technology to remotely care for recovering COVID-19 patients MILAN, July 28, 2021 /PRNewswire/ -- Leaf Space, a leading provider of ground segment as-a-service (GSaaS) solutions, announced to...
2021-07-28 21:00
1574
Fortacin™ Receives Extremely Encouraging Assessment in US Market Research Analysis
HONG KONG, July 28, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce that Fortacin™, a European,Hong Kong andMacau approved treatment for PE receives a detailed market ass...
2021-07-28 20:05
8854
United Imaging Goes "All-in" for Nashville
HOUSTON, July 28, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, makes its debut at HealthTrust University and its in-person debut at AHRA inNashville over the next two weeks. At both events, the company will focus on several unique ...
2021-07-28 20:00
1657
GenScript Announces Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Kit
PISCATAWAY, N.J., July 28, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance...
2021-07-28 19:30
5650
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
* Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase1b/2 trial in South Korea * Efineptakin alfa in patients with GBM showed a 83.3% survival ratio over one year in a phase 1 trial in the U.S. SHANGHAI and GAITHERSBURG, Md., July 28, 20...
2021-07-28 19:15
4657
BIOTRONIK Applauded by Frost & Sullivan for Its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm
LONDON, July 28, 2021 /PRNewswire/ -- Based on its recent analysis of the Global market for implantable cardiac monitoring devices,Frost & Sullivan recognizesBIOTRONIK with the 2021 Global Enabling Technology Leadership Award. The company's subcutaneous miniature, injectable electrocardiogram (EC...
2021-07-28 18:00
1630
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
SHANGHAI, July 28, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive...
2021-07-28 17:13
2546
CUHK Develops a Novel Faecal Test that can Detect Polyps and Early Colon Cancers with Sensitivity Over 90%
HONG KONG, July 28, 2021 /PRNewswire/ -- The faecal immunochemical test (FIT) is commonly used to screen for colorectal cancer but it has low sensitivity (around 50%) for early cancer detection and fails to detect polyps. The Faculty of Medicine at TheChinese University of Hong Kong (CU Medicine)...
2021-07-28 15:09
4471
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of...
2021-07-28 13:47
5509
Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System
HANGZHOU, China, July 28, 2021 /PRNewswire/ -- On July 27, 2021, Venus Medtech ( Hangzhou) Inc. ("Venus Medtech") (stock code: 2500.HK), a leading provider of comprehensive interventional heart valve therapy solutions inChina, and its controlling subsidiary Renaly Ltd., announced that Professor...
2021-07-28 11:41
5504
India-based MedTel receives investment term sheet from Catalist-listed Metal Component Engineering (MCE, SGX:5DX)
SINGAPORE, July 28, 2021 /PRNewswire/ -- Catalist-listed Metal Component Engineering Limited ("MCE") is pleased to announce that it has, through its subsidiary, Metal Precision Services Pte Ltd, entered into a term sheet to take an equity stake in MedTel Healthcare Private Limited ("MedTel"). MCE...
2021-07-28 11:36
11818
More than Half of Singaporeans Unaware of Link between Viral Hepatitis and Liver Failure: Survey
* New survey demonstrates general apathy among Singaporeans towards liver health, particularly among those aged 25 and below, despite high rates of liver cancer and failure in the country * Hepatitis B causes 60-70% of total number of liver cancer cases in the country[1]; liver cancer known ...
2021-07-28 11:00
1881
Gilead Sciences Announces Launch of Asia Pacific ALL4LIVER Grant 2021
– Biennial Grant Program Supports Community Projects Focused on Improving Education About Liver Health inSingapore and 10 Other Countries and Territories– – Inaugural Cycle of the Grant will Focus on Hepatitis B Awareness Initiatives – SINGAPORE, July 28, 2021 /PRNewswire/ -- Gilead Sciences, I...
2021-07-28 11:00
3948
Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
* HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analogs group with greater HBsAg reduction observed in patients with HBsAg ≤ 500 IU/mL at baseline while no HBsAg reduction was observed for the placebo plus nucleos(t)ide analogs group * Receptor oc...
2021-07-28 08:30
3323
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 300 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
Building the Run: Xtep Charts a New Community Ecosystem in Southeast Asia
2026-01-20 17:49
7062
